Dan Wychulis Appointed as Chief Executive Officer of LifeSci Capital
July 01 2024 - 8:49AM
LifeSci Capital LLC, a research-driven investment bank focused on
the life sciences, today announces the appointment of Dan Wychulis
as Chief Executive Officer, effective immediately.
Mr. Wychulis brings extensive capital markets-related experience
to LifeSci Capital, with a broad background spanning equities,
corporate finance, research, institutional sales, corporate access,
strategy, and business development. Prior to joining LifeSci
Capital, he spent eight years at BTIG, most recently serving as
Co-head of Global Equities and, prior to that, as Head of U.S.
Strategy and Franchise Sales. He recently served on BTIG’s
Executive Committee, Global Operating Committee, Capital Markets
Advisory Committee, and Commitment Committee. Before BTIG he spent
15 years at the JMP Group, where he led the firm’s institutional
equity research sales force, held senior institutional sales roles,
and was a Vice President within corporate finance. Mr. Wychulis
began his Wall Street career in corporate finance at Sandler
O’Neill & Partners, focusing on mergers and acquisitions. He
holds a B.A. in government with a concentration in international
relations from Georgetown University.
“We are thrilled to welcome Dan to our team. His vast financial
industry expertise and strong relationships will be invaluable as
we continue to expand our presence in the life sciences sector,”
said Andrew McDonald, Ph.D., Co-Founder of LifeSci Capital.
"LifeSci Capital is on a robust growth trajectory, and I am
confident that Dan is the right leader to further enhance our
offering to corporate clients and investors."
Mr. Wychulis commented, “LifeSci Capital has established itself
as a truly differentiated firm in healthcare finance. It is an
important segment within the LifeSci Partners network of companies,
which together provide high value professional services to life
sciences companies from inception to maturity. I am excited by the
opportunity to build on this success, and lead the firm into its
next level of growth. I look forward to working closely with the
talented team here to innovate, drive strategic initiatives, and
deliver exceptional value to our clients."
LifeSci Capital continues to solidify its position as a premier
banking partner in the mid-tier healthcare sector, having helped to
raise over $6.5 billion across 35 financing transactions over
approximately the last 18 months.
LifeSci Capital
(www.lifescicapital.com) (Member: FINRA/SIPC) is a
research-driven investment bank registered with the U.S. Securities
and Exchange Commission (“SEC”) and the Financial Industry
Regulatory Authority (“FINRA”) that provides corporate finance,
strategic advisory, and equity research services to corporate and
institutional investors. The firm’s highly accomplished team
specializes exclusively on life science companies that discover,
develop, and commercialize innovative products, and is uniquely
positioned to work closely with corporate clients to establish and
execute their financing and strategic initiatives. LifeSci
Capital’s research product, led by its Alpha Series and KOL Series
offerings, is highly differentiated and provides the
investment community with a deep understanding of companies across
therapeutic indications that are both within and beyond our
coverage universe.
LifeSci Partners is the leading provider
of strategic healthcare advisory services in the areas of Investor
Relations, Strategy Consulting, Strategic Partnering,
Communications, Capital Market Services, Venture and Mutual Fund
Investing, Executive Search and On Demand Talent with global
operations across North America, Europe, Israel and Asia. The firm
has a presence in New York, Boston, San Francisco / Silicon Valley,
Chicago, Charlotte, London, Geneva, Paris, Milan, and Tel-Aviv.
LifeSci leverages global relationships and local knowledge in
multiple territories around the world to provide high-value
services for clients. The firm has an experienced team drawing from
diverse Wall Street, scientific, and communications backgrounds to
successfully plan and implement strategic programs for public and
private life sciences companies of all sizes and stages.
Contacts
Andrew McDonald, Ph.D.LifeSci Capital, LLCPhone:
646-597-6987andrew@lifescicapital.com
Michael RiceLifeSci Capital, LLCPhone:
646-597-6979mrice@lifescicapital.com
For additional information about LifeSci Capital and its
services, please visit www.lifescicapital.com.